SCOTUS Backs Hikma Skinny-Label Win on Vascepa; ADC Therapeutics Crashes 50% on Death

Takeda books a two-and-a-half-billion-dollar legal provision and swings to a full-year loss — just as its biggest pipeline bet delivers Phase 3 results in gastric cancer.

Plus Alnylam commits two billion to AI-driven RNA discovery, Roche pushes incretins into type 1 diabetes, and a House committee tells the FDA to speed up INDs.

Welcome to The Pharma Closeout for Friday, June 5th, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's close out the week. ### [TOP STORY] — Takeda's $2.5B Legal Hit Meets Innovent ADC Validation

Takeda adjusted its full-year 2025 financials to reflect a significant legal provision after a U.S. jury found the company liable in damages. The case centered on Amitiza, where the jury determined Takeda delayed generic competition through a pay-for-delay scheme. Damages were apportioned across direct purchasers like pharmacies and wholesalers, insurers, and individual retailers. Takeda has vowed to appeal, but the provision — nearly three times the headline damages figure — tells you their risk calculus accounts for treble exposure. It swung the entire fiscal year to a loss.

And the timing couldn't be worse. Julie Kim is set to take over as CEO this month, succeeding Christophe Weber. She inherits one of the largest single legal charges in recent pharma history on day one — a financial overhang she didn't create but now has to navigate before she can set her own strategic agenda.

Here's the other side of Takeda's ledger, though. Innovent Biologics declared Phase 3 success for arcotatug tavatecan — their CLDN18.2 antibody-drug conjugate — in advanced refractory gastric cancer. The G-HOPE-001 trial hit its primary endpoint at the first interim analysis. This is the asset underpinning a significant multi-billion-dollar partnership between Takeda and Innovent. Let's bring in Marcus Webb on this one.

And this data lands one day after the Zynlonta safety questions we flagged yesterday. The ADC space is under tighter scrutiny than it was even a month ago — arcotatug tavatecan clearing a Phase 3 hurdle at interim gives Takeda and Innovent a differentiation argument, but confirmatory data still needs to hold. The market's tolerance for ADC risk has tightened considerably.

The read-through: Takeda's incoming CEO has a pipeline story to tell, but the legal overhang could constrain the company's ability to chase additional deals. That matters in a year where biopharma M&A activity has surged significantly, on pace for the strongest year since pre-pandemic levels. Flexibility is currency right now, and Takeda just spent a lot of it.

Shifting to the deal roundup — while Takeda manages that overhang, other companies are deploying capital aggressively. Alnylam signed its first AI discovery partnership, linking up with RNA specialist Inceptive in a deal potentially worth two billion dollars. Inceptive's platform will help Alnylam prioritize development candidates and accelerate its research timeline.

AI in RNA therapeutics isn't the debate — the design rules are better understood than in small molecules, which makes computational acceleration genuinely tractable. What matters is how much timeline compression Alnylam actually captures. Even shaving six months off lead optimization changes the economics of a two-billion-dollar commitment substantially.

In mid-stage data, Lundbeck is advancing bocunebart into further development after Phase IIb results from the PROCEED trial in migraine prevention. In the intravenous arm, the drug demonstrated a meaningful reduction in monthly migraine days over the first twelve weeks compared to placebo, in patients with prior preventive treatment failures. Wall Street's read was mixed, but Lundbeck says the totality of data supports moving forward.

While the separation from placebo is modest, bocunebart targets PACAP rather than CGRP, a differentiated mechanism. The pivotal question for Lundbeck isn't the top-line number — it's whether patients who've already failed anti-CGRP therapy show differential response to PACAP blockade. That subgroup analysis is what turns a crowded eight-billion-dollar migraine market into a defensible niche.

Two more to flag quickly. Roche reported positive Phase 2 data for acmopatide, its incretin shot, in type 1 diabetes, showing improvements in glycemic control and insulin requirements. And Nyxoah, the sleep apnea device company, cratered roughly 40.6 percent in a single session. No clear explanation from available disclosures yet — we'll update when details surface.

On acmopatide — in type 1, that 15 percent insulin reduction is the more clinically meaningful endpoint. Hypoglycemia burden scales directly with exogenous insulin dose, so insulin sparing while maintaining glycemic control reduces time below range. If Roche can show durability without ketoacidosis risk in longer studies, they've carved out a GLP-1 lane that neither Novo nor Lilly has staked out yet. ### [REGULATORY WATCH] — Maya leads

On the regulatory front, a House committee directed the FDA to accelerate its IND review and sign-off process. Specific timelines aren't public yet, but for small biotechs burning cash between preclinical work and first-in-human dosing, faster IND turnaround directly reduces the capital needed to reach proof-of-concept. That's a runway extension without a dilutive raise.

Running parallel to that, the BINSA bill — Biotech Investment National Security Act — introduced by Representative Moolenaar and Congresswoman Dingell, would add biotechnology to the COINS Act and put greater scrutiny on licensing deals with China-based drugmakers. Worth noting: the kind of ex-China partnership structure Takeda and Innovent are using would fall squarely under that lens — as would dozens of similar deals across the industry.

Separately, the FDA is proceeding with a safety study on mifepristone, per the Wall Street Journal. Mifepristone accounts for the majority of U.S. abortions, and a safety study could create a regulatory pathway to distribution restrictions regardless of what the data ultimately show. The process itself becomes the lever.

And at this week's CNPV hearing on the Commissioner's priority voucher program, industry support met skepticism from outside experts who say the program has made political influence in the review process easier to exert. If the program gets paused, companies banking on expedited timelines will need to recalibrate their submission strategies.

Three regulatory threads this week — IND acceleration, deal scrutiny, voucher uncertainty — all pointing to the same conclusion. Companies planning submissions for late 2026 and into 2027 should be scenario-planning for a regulatory environment that looks materially different from what they modeled six months ago.

Looking ahead — the marquee date is June 19th, when the FDA rules on Merck's WELIREG plus KEYTRUDA combination in renal cell carcinoma. In the LITESPARK-022 trial, the combination therapy demonstrated a clinically meaningful reduction in the risk of disease recurrence or death versus KEYTRUDA monotherapy. Also on the June calendar: Spero Therapeutics is awaiting an FDA decision on its antibiotic for complicated urinary tract infections.

And EHA 2026 opens June 11th — we flagged Legend Biotech's LB2501 data yesterday as a headline to watch in the hematology space.

Between the Merck PDUFA, the Spero decision, and EHA, the next two weeks could substantially reshape competitive positioning across oncology and hematology. No shortage of catalysts.

That's your Pharma Closeout for Friday, June 5th, 2026. Takeda's legal charge colliding with Innovent's ADC validation. Alnylam betting two billion on AI-powered RNA discovery. Roche opening a new incretin lane in type 1 diabetes. And a week where Congress, the FDA, and the courts all reminded us that the regulatory landscape is a variable, not a constant. If this briefing saves you time, follow us on Spotify and drop a rating — it helps other pharma professionals find the show.

Go enjoy your weekend. We'll see you Sunday.